Cargando…

Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial

BACKGROUND: Anastrozole has been associated with substantial accelerated bone mineral density (BMD) loss during active treatment. METHODS: One thousand four hundred and ten women were included in a BMD substudy and stratified into three strata according to their baseline T-score at spine or femoral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sestak, Ivana, Blake, Glen, Patel, Raj, Cuzick, Jack, Howell, Anthony, Coleman, Robert, Eastell, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039042/ https://www.ncbi.nlm.nih.gov/pubmed/33495601 http://dx.doi.org/10.1038/s41416-020-01228-2

Ejemplares similares

Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia
por: Sestak, Ivana, et al.
Publicado: (2019)

Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
por: Cuzick, Jack, et al.
Publicado: (2020)

Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
por: Forbes, John F, et al.
Publicado: (2016)

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)
por: Smith, Samuel George, et al.
Publicado: (2017)

Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial
por: Hale, Michael J., et al.
Publicado: (2020)

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
por: Cuzick, Jack, et al.
Publicado: (2015)

Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II
por: Sestak, I, et al.
Publicado: (2018)

The effect of anastrozole on bone mineral density during the first 5 years of adjuvant treatment in postmenopausal women with early breast cancer
por: Inoue, Hiroaki, et al.
Publicado: (2015)

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial
por: Sestak, I, et al.
Publicado: (2012)

Effects of cyclin D(1 )gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study
por: Lundgren, Katja, et al.
Publicado: (2012)

Markers for the identification of late breast cancer recurrence
por: Sestak, Ivana, et al.
Publicado: (2015)

Ibis
por: Vargas Vila, José María, 1860-1933
Publicado: (1908)

Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial
por: Markopoulos, Christos, et al.
Publicado: (2012)

Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ
por: Lo, Louisa Lisa, et al.
Publicado: (2018)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020)

Impact of preventive therapy on the risk of breast cancer among women with benign breast disease
por: Cuzick, Jack, et al.
Publicado: (2015)

Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer
por: Anderson, T J, et al.
Publicado: (2002)

Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women
por: Gangadhara, Sharath, et al.
Publicado: (2009)

Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
por: Bojanić, Kristina, et al.
Publicado: (2018)

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5
por: Dowsett, Mitch, et al.
Publicado: (2018)

The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies
por: Smith, Samuel G., et al.
Publicado: (2021)

Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
por: Aydiner, Adnan, et al.
Publicado: (2008)

Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
por: Brentnall, Adam R., et al.
Publicado: (2020)

Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial
por: Lester, J.E., et al.
Publicado: (2012)

Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors
por: Sestak, Ivana, et al.
Publicado: (2016)

“Keeping the Boogie Man Away”: Medication Self-Management among Women Receiving Anastrozole Therapy
por: Wickersham, Karen, et al.
Publicado: (2012)

Anastrozole (‘Arimidex’) blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer
por: Miller, W R, et al.
Publicado: (2002)

Correlation Between Anthropometric Measures and Biomarker Changes After Neoadjuvant Therapy With Tamoxifen or Anastrozole in Postmenopausal Women With Breast Cancer
por: Cintra, Karine A., et al.
Publicado: (2010)

Effects of psoralen on the pharmacokinetics of anastrozole in rats
por: Zhang, Yuzhu, et al.
Publicado: (2018)

The spreading of the invasive sacred ibis in Italy
por: Cucco, Marco, et al.
Publicado: (2021)

A Comparison Controlled Study Examining Outcome for Children With Autism Receiving Intensive Behavioral Intervention (IBI)
por: Wójcik, Marta, et al.
Publicado: (2023)

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
por: Dowsett, M, et al.
Publicado: (1999)

Anastrozole (Arimidex ™) – an aromatase inhibitor for the adjuvant setting?
por: Buzdar, A U
Publicado: (2001)

The Sacred Ibis debate: The first test of evolution
por: Curtis, Caitlin, et al.
Publicado: (2018)

The Genomic Footprints of the Fall and Recovery of the Crested Ibis
por: Feng, Shaohong, et al.
Publicado: (2019)

Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events
por: Kim, Yoo Jung, et al.
Publicado: (2020)

Anxiety Levels Predict Bone Mineral Density in Postmenopausal Women Undergoing Oral Bisphosphonates: A Two-Year Follow-Up
por: Martino, Gabriella, et al.
Publicado: (2021)

Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation
por: Regenthal, Ralf, et al.
Publicado: (2018)

Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole
por: Gorski, Justin Wayne, et al.
Publicado: (2017)

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
por: Geisler, J., et al.
Publicado: (1996)

Cannot write session to /tmp/vufind_sessions/sess_rfirb8uton6iju5d45tqluumki